Enhancing immune responses with immune-modulatory monoclonal antibodies directed to inhibitory immune receptors is a promising modality in cancer therapy. Clinical efficacy has been demonstrated with antibodies blocking inhibitory immune checkpoints such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) or PD-1/PD-L1. Treatment with ipilimumab, a fully human CTLA-4-specific mAb, showed durable clinical efficacy in metastatic melanoma; its mechanism of action is, however, only partially understood. This is a study of 29 patients with advanced cutaneous melanoma treated with ipilimumab. We analyzed peripheral blood mononuclear cells (PBMCs) and matched melanoma metastases from 15 patients responding and 14 not responding to ipilimumab by multicolor flow cytometry, antibody-dependent cell-mediated cytotoxicity (ADCC) assay, and immunohistochemistry. PBMCs and matched tumor biopsies were collected 24 h before (i.e., baseline) and up to 4 wk after ipilimumab. Our findings show, to our knowledge for the first time, that ipilimumab can engage ex vivo FcγRIIIA (CD16)-expressing, nonclassical monocytes resulting in ADCC-mediated lysis of regulatory T cells (Tregs). In contrast, classical CD14
CD16
− monocytes are unable to do so. Moreover, we show that patients responding to ipilimumab display significantly higher baseline peripheral frequencies of nonclassical monocytes compared with nonresponder patients. In the tumor microenvironment, responders have higher CD68
+

/CD163
+ macrophage ratios at baseline and show decreased Treg infiltration after treatment. Together, our results suggest that anti-CTLA-4 therapy may target Tregs in vivo. Larger translational studies are, however, warranted to substantiate this mechanism of action of ipilimumab in patients.
monocytes | macrophages | Tregs | ipilimumab | ADCC T he clinical benefit of immune checkpoint blockade represents arguably one of the most significant advances of modern oncology, as it has definitively proven to produce substantial clinical responses, not only in tumors traditionally perceived as "immunogenic" but also in a variety of solid tumors (1) . Two pivotal phase III clinical trials in patients with advanced melanoma of the fully human, anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) IgG1 monoclonal antibody ipilimumab (Yervoy; previously MDX-010; Medarex/Bristol Myers-Squibb) reported significantly increased overall survival, which led to its approval by the US Food and Drug Administration (2, 3) . Ipilimumab represents the first of a new class of cancer therapies that function by enhancing host antitumor immunity. However, clinical benefit following immune checkpoint blockade of CTLA-4 is limited to a fraction (10-15%) of treated patients, and the mechanism(s) of action are still poorly understood. Moreover, no reliable biomarkers of clinical efficacy are available to date. Although CTLA-4 belongs to the family of inhibitory lymphocyte receptors, it does not appear to transmit inhibitory signals into effector T cells (4) . Rather, CTLA-4 may control key functions of regulatory T cells (Tregs) and of antigen-presenting cells (5-7).
More recently, studies in mice revealed that the antitumor activity of CTLA-4 blockade is mediated by Fc gamma receptor (FcγRIV)-expressing macrophages in the tumor microenvironment (TME) via in trans depletion of tumor-infiltrating Tregs (8) (9) (10) . We speculated that a similar mechanism might operate in melanoma patients, who show a response to ipilimumab. To investigate this hypothesis, we interrogated peripheral blood mononuclear cells (PBMCs) and matched melanoma metastases from 15 patients responding and 14 nonresponding to ipilimumab. responses, defined as partial response (PR) or complete response (CR), and of patients who showed progression of disease after treatment with ipilimumab. Objective responses included 2 CRs and 13 PRs. By multicolor flow cytometry, we identified three different monocyte subsets according to their surface expression of HLA-DR, CD14, and CD16 ( Fig. S1 ) (12) . Interestingly, patients responding to ipilimumab displayed the highest percentages ( Fig. 1 A and D) and absolute counts (Fig. 1B ) of circulating nonclassical, FcγRIIIA(CD16)-expressing monocytes at baseline (12) (13) (14) , whereas there was no difference in the frequency of classical monocytes (CD14 Fig. 1 A, B, D, and E) and of CD16-expressing natural killer (NK) cells between responding and nonresponding patients (Fig. S2) . The human, nonclassical FcγRIIIA/CD16 ++ monocyte subset is characterized by high expression levels of surface HLA-DR, CD16, and CD11c and low expression levels of surface CD14, CD11b, and CD163 (Fig. 1C) (19, 20) , postsort flow cytometric analysis confirmed that the vast majority 
Results
++ CD16 − ;
CD16
+ Macrophages in the TME of Patients Responding to Ipilimumab. To investigate the TME, we studied matched pre-and postipilimumab metastatic lesions from 13 patients with melanoma and assessed by immunohistochemistry (IHC) the presence of CD8
+ Tregs, and CD68 + or CD163 + macrophages in the tumor nests. Tissue from melanoma metastases was obtained according to the study protocol at baseline and 3-4 wk after the last ipilimumab dose from shrinking lesions from responding patients or progressing lesions from nonresponding patients, respectively. Whereas, at baseline, Foxp3
+ tumor-infiltrating Treg counts were similar in responding vs. nonresponding patients (Fig. 3A) , they were significantly lower in postipilimumab lesions from responding patients than in those from nonresponding patients ( Fig. 3 A and B ). Tregs are a major component of the immunosuppressive microenvironment of melanoma-infiltrated lymph nodes, and their depletion may favor an immune-promoting TME (23) . We evaluated macrophage infiltration of melanoma lesions by assessing the distribution of CD68 + and CD163 + cells. We initially evaluated the distribution of CD68, a well-established macrophage marker. Melanoma-infiltrating CD68 + macrophages were present in melanoma metastases (Fig. 3C) . As tumor-associated macrophages represent a heterogeneous population with distinct immune properties, we set out to further evaluate the distribution of CD163 + macrophages (Fig. 3C ). CD68 + and CD163 + macrophages from our patients expressed CD16 (FcγRIIIA; Fig. 3C ). At baseline, responding patients had increased CD68
+ /CD163 + ratios compared with nonresponding patients (Fig. 3D) . Next, to quantify more precisely the colocalization of CD16-and CD68-or CD163-expressing cells on the same tissue section at baseline, we used an automated staining and a standardized acquisition technique by assessing the coexpression of each of two markers in three representative tumor regions ( Fig. 3 E and F) . Consistent with our previous observations, responding patients had significantly higher intratumoral CD16 +
CD68
+ cell densities than nonresponding patients. In contrast, the latter displayed higher CD16 +
CD163
+ densities (Fig. 3E) . Finally, we did not find any significant differences in CD8 + T-cell infiltrate in responding vs. nonresponding patients, and CD56 + NK cell infiltrates were negligible for both patient groups and time points (Fig. 3C ).
Discussion
Immune checkpoint blockade arguably represents a milestone in modern medicine, and will likely become a major treatment option for patients with cancer, with increased long-term efficacy at reduced toxicity. However, immune checkpoint blockade works well in only a 
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+ CD25 neg T cells, respectively. Data represent the averages ± SD from three or four independent experiments (**P < 0.01 and ***P < 0.001, unpaired two-tailed Student t test).
fraction of treated patients. Possible cause(s) for the lack of response to checkpoint blockade remain still largely unknown, as do the appropriate biomarkers for patient selection. Preclinical studies highlight macrophages as key innate effector cells mediating ADCC in mice, although this remains unresolved in humans (8) (9) (10) .
Our results show that, as opposed to nonresponders, patients responding to ipilimumab treatment display the highest peripheral counts of nonclassical monocytes at baseline. This monocyte subset has been associated to the patrolling of blood vessels' endothelium and the sensing of nucleic acids, and it is characterized for the secretion of Th1-polarizing cytokines (12) . The murine FcγRIV is the ortholog of human FcγRIIIA (15) and its expression pattern on Ly6C lo murine monocytes is consistent with the corresponding nonclassical CD14
+ CD16 ++ monocyte subset in humans, and it selectively mediates IgG-dependent effector functions in vivo (14, (16) (17) (18) (24) .
Effective tumor control may be achieved by shifting the balance from immune tolerance to protective immune responses that eliminate cancer cells. Compared with baseline, only responding patients have decreased levels of intratumoral Tregs in postipilimumab tumor lesions, and, in addition, they display the highest CD68 + /CD163 + macrophage ratio, indicative of a TME enriched with inflammatory macrophages. CD163 is a scavenger receptor for the hemoglobin-haptoglobin complex and is typically expressed by immune-suppressive macrophages (known as M2-like) (25) , which have been associated with poor prognosis in patients with early-stage melanoma (26) . CD163 + macrophages are known for secreting immune-suppressive mediators such as IL-10 and TGF-β, low tumoricidal activity, and promotion of tissue remodeling and angiogenesis (27) . On the contrary, CD68 +
CD16
+ are classically activated, M1-like macrophages that secrete inflammatory mediators such as IL-12, TNF-α, and inducible nitric oxide synthase; exhibit antitumor activity; and elicit tumor tissue disruption (28) . Interestingly, both CD68 + and CD163 + macrophages from our patients express CD16 (FcγRIIIA; Fig. 3C ). The higher baseline CD68 +
/CD163
+ ratio and density of CD16 
CD163
+ cells in the melanoma lesions from responding patients, may reflect an immune-inflammatory TME enriched with a beneficial macrophage population. However, we cannot conclusively prove that the macrophages identified in the TME are ultimately responsible for the intratumoral depletion of Tregs in vivo. Furthermore, whether the observed reduction in Tregs is mechanistically significant remains an unresolved puzzle. Nevertheless, our data are hypothesisgenerating and suggest that the increased CD8 + /Treg ratio in responding lesions may result from ADCC of intratumoral Tregs. Studies of combined GVAX/CTLA-4 blockade in the B16 murine melanoma model and patients with melanoma previously highlighted the importance of CD8 T cells in the TME (29, 30) . We did not find, however, any significant differences in CD8 + T-cell infiltrate in responding vs. nonresponding patients.
We recognize the inherent limitations of the present study caused by its small sample size. Studies on larger datasets are required to validate prospectively baseline classical and nonclassical blood monocytes, CD68
+ macrophage ratios, and CD16
+
CD68
+ cellular density in the TME as potential biomarkers of response to ipilimumab treatment. Critical mechanistic questions remain still open, particularly whether the observed reductions in Tregs are mechanistically significant, and whether the macrophages identified in the TME are ultimately responsible of such reduction in vivo. Moreover, from a clinical standpoint, it is unclear whether the depletion of Tregs in the TME is required for efficacy of ipilimumab; based on preclinical work, there is indeed uncertainty whether the mechanism of action of anti-CTLA-4 treatment is caused by effector T-cell expansion and/or Treg depletion.
Future novel techniques will likely contribute to improve the phenotypic and functional characterization of melanoma-associated macrophages and other potential effector cells, hopefully enabling the investigation of cell subsets with selective IgG-dependent effector properties in vivo. The present study provides insight for 
/CD163
+ macrophage ratio in melanoma lesions at baseline from eight nonresponding patients and five responding patients, respectively. Error bars indicate mean ± SD (***P < 0.001, paired two-tailed Student t test). (E) Baseline density of colocalization, defined as percentage of CD16 and CD68 or CD163 expression of each of two markers in three representative tumor regions per sample. Box plots show the medians and interquartile ranges (25th to 75th percentiles), with whiskers approximating 95% of the data. The line in the middle of the box is plotted at the median; the plus sign represents the mean (Tukey method; **P < 0.01 and *P < 0.05 for CD16 + CD68 + or CD16 + CD163 + cellular density in responders vs. nonresponders, respectively, paired two-tailed Student t test). a potential mechanism of action of ipilimumab treatment, highlighting the contribution of multiple host-dependent factors. If confirmed in larger patient datasets, our results may contribute to the generation of much-needed predictive biomarker panels, antibody design, and the development of rational, synergistic combination therapies that mobilize relevant immune effector cells to promote anticancer immunity.
Methods
Human Cells, Patient Population, and Study Design. Human sample collection and use adhered to the study protocols approved by the institutional review and privacy boards of the University Hospital of Lausanne, Switzerland (protocol N: 400/11-IPI-Biology) and the University Medical Center, Tübingen, Germany (protocol N: 43/2008BO1), and the local ethics committee in accordance with the Helsinki Declaration. Patients gave informed consent before study inclusion. Healthy volunteers or patients provided peripheral blood withdrawn by using tubes containing Li-heparin-coated beads (Sarstedt). Blood was centrifuged for 10 min at 210 × g for plasma preservation, followed by PBMC preparation by gradient centrifugation using Lymphoprep (Ficoll equivalent; Axis-Shield). All cells were used fresh or after cryopreservation. Viable cell recovery was consistently 85-100%. Patients in this study were diagnosed with metastatic melanoma and received a maximum of four cycles of 3 mg/kg ipilimumab i.v. every 3 wk upon disease progression with at least one prior treatment. Blood samples were withdrawn at baseline, during treatment, 20 d after treatment, and then monthly for as long as 14 mo after the last ipilimumab dose. anti-CD11c-PE-Cy7 (isotype IgG1κ; eBioscience), anti-PD-L1 (isotype IgG1, κ; BD Biosciences), anti-CD163-APC (isotype IgG1κ; R&D Systems), anti-PD-L2-APC (isotype IgG1κ; BD Biosciences); anti-CD11b-Alexa700 (isotype IgG1κ; BD Biosciences), anti-CD14-Pacific Blue (isotype IgG2aκ; BD Biosciences); anti-CD3-FITC (isotype IgG1; Beckman Coulter), anti-CD19-FITC (isotype IgG1; Beckman Coulter), anti-CD20-FITC (isotype IgG2bκ; BioLegend), anti-CD56-FITC, and anti-NKp46-FITC (isotype IgG1κ; BioLegend), and Vivid-Green (Invitrogen-Molecular Probes) was used as a live/dead marker. Negative controls included directly labeled and unlabeled isotype-matched irrelevant mAbs. Results were calculated as geometric mean of fluorescence intensity (gMFI). All results were analyzed by using FlowJo software, version 9.6.4.
IHC Staining and Evaluation. IHC was performed on 4-μm paraffin sections from complete excisions of progressing or partially regressing melanoma lesions and from core biopsy specimens of completely regressing lesions. The following primary mouse mAbs were used: anti-CD68 (clone PG-M1, 1:200 dilution; Dako), anti-CD163 (clone 10D6, 1:200 dilution; Novocastra), anti-CD8 (clone C8/144B, 1:50 dilution; Dako), anti-CD56 (clone 1B6, 1:50 dilution; Novocastra), anti-CD16 (clone 2H7, 1:80 dilution; Novocastra), and anti-Foxp3 (clone 150D, 1:50 dilution; BioLegend). Slides were placed on a BenchMark XT IHC/ISH staining module (Ventana; Roche), for deparaffinization, endogenous peroxidase quenching, and epitope retrieval. For CD68, CD163, CD8, and CD56, the ultraView Universal DAB Detection Kit (Ventana) was used, whereas, for CD16 and Foxp3, the Envision+ System HRP-labeled Polymer with Liquid DAB+ Substrate Chromogen System (both from Dako) was used. The ratio of CD68 + cells and CD163 + cells was quantified in serial sections from all samples analyzed. All stains included a negative control with a matched Ab isotype, whereas staining of tonsillar sections served as positive controls for all antibodies. The percentage of tumor-infiltrated lymphoid populations was scored by visual inspection by using a 40× objective. (Magnification, 400×.) Areas of maximum infiltrates from the periphery of the tumors were selected and counted blindly. For double CD16/CD68 and CD16/ CD163 immunostaining (Discovery Ultra staining module; Ventana), the following primary antibodies were used: ready-to-use rabbit mAb, clone SP175 (Ventana-Roche); mouse mAb, clone PG-M1; and mouse mAb, clone 10D6 (both at 1:200 dilution). For CD16 detection, the UltraMap anti-Rb-alkaline phosphatase multimer detection kit (Ventana) was used, and a blue-color reaction was obtained with nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP). For CD68 and CD163 detection, the OmniMap anti-Ms-HRP multimer detection kit (Ventana) was used and a brown color was obtained with DAB. Stained slides were scanned in a batch format by using the Vectra multispectral imaging system (Perkin-Elmer), and the same regions of the acquired 4× images of CD16/CD68-and CD16/CD163-stained slides were collected. Then, 20× multispectral images were acquired from the collected areas and processed by using inForm tissue finder software (PerkinElmer). For unmixing of the images and analysis, the spectral libraries of hematoxylin as well as of both chromogens were generated. The percentages of CD68 and CD163 that colocalized with CD16 within the tumor areas were calculated through a thresholded colocalization analysis. Thresholds used to determine the cutoff for all three antibody stains were set visually.
Tumor Response Assessment. Tumor response was assessed at weeks 12, 16, and 24 after treatment with ipilimumab by using the immune-related response criteria (11) Patients achieving CR, PR, or stable disease at week 16/24 after ipilimumab treatment were considered responders. Patients with progressive disease at week 16/24 after ipilimumab treatment were considered nonresponders.
Monolayer of Cells. In the sample chamber, 200 μL of sorted cell suspension (containing ∼40,000 cells) was placed, and smears were carried out at 28 × g for 5 min by using Shandon Cytospin 4 (Thermo Scientific). After centrifugation, the sample was dried with cold air and stained with Giemsa (Fluka) by using Romanowsky staining.
Statistical Analysis. Statistical analyses were made by Stata 13.0 (StataCorp) or GraphPad Prism, version 6. Error bars in figures represent the SEM or SD calculated by using GraphPad Prism. Specific statistical tests used were paired or unpaired two-tailed Student t test and ANOVA.
